- About Us
- Healthcare Companies
- Pharmacy Solutions
- Healthcare Professionals
- Contact Us
- MyAH Portal
Class 2 Recall
24 Aug 2020
Sanofi has informed us of an Out Of Specification (OOS) result which was detected for Rasburicase enzyme activity according to a specific method and specifications for US market, at 12 months stability time point. Sanofi is recalling Fasturtec® 7.5 mg (Rasburicase) Solution for IV infusion - 7.5 mg/5 ml (Injectable powder in vial packaged with 5 ml solvent in ampoule), batch number A9306 as a precautionary measure.
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
|PIP Code||Product Description||Supplier||Affected Batch|
|3338928||Fasturtec® 7.5 mg. 1.5 mg/ml powder and solvent for concentrate for solution for infusion||Sanofi||A9306|
For medical information enquiries please contact firstname.lastname@example.org Med Info Phone :0800 035 25 25.
For stock control enquiries please contact GB-CustomerServices@sanofi.com Phone number: 0800 854 430
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
Please note that Alliance Healthcare do not stock and we are not accepting stock returns.
If you have any questions, then please contact your local Service Centre Customer Services team.